Kazutoshi Isobe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kazutoshi Isobe has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Kazutoshi Shibuya
Department of Surgical Pathology, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
6 shared publicationsSakae Homma
Division of Respiratory Medicine, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
5 shared publicationsYoshinobu Hata
Division of Thoracic Surgery, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
5 shared publicationsYujiro Takai
Division of Respiratory Medicine, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
5 shared publicationsGo Sano
Division of Respiratory Medicine, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
4 shared publicationsSusumu Sakamoto
Division of Respiratory Medicine, Faculty of Medicine, Toho University Omori Medical Center, Tokyo 143‑8541, Japan
4 shared publications
Latest Publications
- 22 June 2015
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 3 (5) , 1058-1062
Thymoma exhibiting spontaneous regression in size, pleural effusion and serum cytokeratin fragment level: A case report
A 30-year-old man was admitted to Toho University Omori Medical Center for assessment of right chest pain and fever. Chest computed tomography (CT) revealed an anterior mediastinal tumor sized 11.0x6.0x5.0 cm, with right pleural effusion. The laboratory analysis revealed elevated white blood cell count (11,000/µl), C‑reactive protein (4.1 mg/dl) and cytokeratin fragment (CYFRA; 12.7 ng/ml; normal, Introduction Thymoma is derived from thymic epithelial cells and is one of the most common neoplasms in the anterior mediastinum (1). The overall incidence of thymoma is 0.15 cases per 100,000 individuals and the majority of the patients with thymoma or thymic carcinoma are aged 40–60 years (2,3). The World Health Organisation (WHO) classification is based on histological analysis of epithelial cell atypia and the degree of infiltration of non-neoplastic lymphocytes (4). Although the great majority of these tumors exhibit more conventional histological characteristics, unusual types have also been described, such as sclerosing thymoma (5). Spontaneous regression (SR) of thymoma without therapy has been reported, although its incidence is rare (6–8). This is the case report of a patient with thymoma exhibiting SR and disappearance of the pleural effusion. Case report A 30-year-old man was admitted to Toho University Omori Medical Center with right chest pain and low-grade fever. The patient was a never-smoker and had no medical history. On physical examination, the temperature was 37.8°C and the respiratory sounds were clear. A chest X-ray revealed a mass shadow in the right hilum and a blunted right costophrenic angle. A chest X-ray obtained 3 months prior had shown minor expansion of the right mediastinum, without any findings of right pleural effusion, but no additional examinations were performed. A chest computed tomography (CT) scan revealed an anterior mediastinal tumor sized 11.0×6.0×5.0 cm, with a right pleural effusion (Fig. 1). The laboratory analysis findings were normal, except for elevations of the white blood cell count (11,000/µl), C-reactive protein (4.1 mg/dl) and serum cytokeratin fragment (CYFRA; 12.7 ng/ml, normal, Time points Day Size, mm Reduction rate, % Pleural effusion CYFRA, ng/ml At first visit 0 110×60×50 – + 12.7 At CTNB 6 100×55×44 26.7 + – After CTNB (7 days) 13 95×54×42 34.7 – – After CTNB (1 month) 35 80×36×30 73.8 – 0.8 [i] CT, computed tomography; CYFRA, cytokeratin fragment; CTNB, CT-guided needle biopsy. The mediastinal mass adhered densely to the upper lobe of the right lung and thymectomy and partial resection of the right upper lobe were performed. The mediastinal mass was composed of a solid part and cystic space (Fig. 5A). In the solid part, there was epithelial cell proliferation admixed with a large number of lymphocytes, which was compatible with who type B2 thymoma (Fig. 5B). The tumor displayed coagulation necrosis and fibrosis, with foamy cell aggregations and cholesterol crystals (Fig. 5C). Microscopic transcapsular invasion was present (Masaoka classification, stage II). By contrast, the cystic wall was lined by a flattened epithelium including a small number of goblet cells. Thymic tissue with Hassall's corpuscles was attached to the thin-walled cyst, which was consistent with a thymic cyst. On immunohistochemical staining (Fig. 5D and E), the tumor was strongly positive for cytokeratin. The postoperative course was uneventful and the patient remains recurrence-free at 1 year after surgery. Figure 5. (A) Macroscopically, the resected specimen was composed of a solid mass with massive necrosis and a cystic space; (B) the mass in the right lobe is composed of epithelial cells admixed with lymphocytes; (C) the tumor included prominent degenerative and necrotic areas; (D) on CD5 immunohistochemical staining, the presence of T lymphocytes was demonstrated; (E) immunohistochemical staining was strongly positive for cytokeratin (AE1/AE3). Discussion SR has been reported in various types of cancer, although it is considered unusual (9). Cole (9,10) reported that immunological reactions play an important role in this rare event (10) and SR of tumors may be caused by necrosis and rupture (9). SR in mediastinal tumors has been reported in renal cell carcinoma, malignant melanoma and neuroblastoma (9). However, SR of thymoma is rare (6–8). Moran and suster (1) reported 25 cases of thymoma with prominent hemorrhagic and necrotic changes, without a detailed description of tumor regression. Thymoma is generally asymptomatic (1) and the majority of the patients with thymoma commonly present with an abnormal chest shadow, while 15% of the cases with thymoma are associated with myasthenia gravis (11). By contrast, all the reported patients with SR of thymoma have presented with symptoms, such as fever or chest pain (Table II). These symptoms may be associated with rapid tumor enlargement prior to regression, as was the case in our patient. One possible cause of the rapid enlargement of thymoma prior to regression has been reported to be disruption of the vascular supply and necrosis and an inflammatory reaction resulting in pleural effusion (6). All the patients with sr of thymoma presented with pleural effusion (Table II), supporting this hypothesis. In the present case, the tumor included prominent degenerative and necrotic areas, which was consistent with previous reports (Table II). Kuo (12) reported that a hemorrhagic and necrotic thymoma may develop into a sclerosing thymoma, due to the absorption of the hemorrhagic and necrotic components. Clinical findings such as fever, chest pain and elevation of serum levels of inflammatory markers are consistent with massive necrosis (12). The cause, mechanism and trigger of regression, as well as the cause of necrosis, have not been clearly determined and remain a hypothesis. Rapid tumor growth may lead to increased internal pressure, resulting in massive necrosis and subsequent tumor regression. In some patients, non-steroidal anti-inflammatory drugs were administered for subjective symptoms. Thymoma regression during corticosteroid treatment has been reported (4) and may be associated with stress and increased steroid levels. Some cases are believed to be caused by vascular insufficiency and thrombus formation (8), which was not observed in our patient. Table II. Reported cases of SR of thymoma. Table II. Reported cases of SR of thymoma. Symptoms Pathological findings No. Author Age, years Gender Chest pain Fever Masaoka stage Necrosis WHO type Size before SR, mm Pleural effusion CYFRA, ng/ml Size after SR, mm Reduction rate, % Duration of SR Refs. 1 Okagawa et al 31 F + + II + B2 60×55×50 + ND 45×40×30 67.3 3 weeks (7) 2 Yutaka et al 47 M + ND I + B3 80×70×60 + 40 60×30×20 89.3 1 month (6) 3 Fukui et al 43 F + ND II + B2 34×34×27 + ND 14×12×8 95.7 1.5 months (8) 4 Fukui et al 32 F + + IV + B2 100×95×79 + ND 73×69×49 63.1 1 week (8) 5 Present case 30 M + + II + B2 110×60×50 + 12.7 80×36×30 73.8 1 month – [i] WHO, World Health Organisation; M, male; F, female; ND, not described; SR, spontaneous regression; CYFRA, cytokeratin fragment. Elevation of CYFRA in the pleural effusion was prominent in the present case, suggesting that the origin of CYFRA may be the epithelial cells of the thymoma. CYFRA has been reported to be a sensitive and specific marker for squamous cell lung cancer, through detecting a fragment of the cytokeratin-19, which is a subunit of the cytokeratin intermediate filament expressed in simple epithelia and their malignant counterparts (13). In the present case, the level of CYFRA was increased in the serum and pleural effusion, which had not been previously reported (Table II). The increased CYFRA levels may be attributed by a collapse of tumor cells and increased cytokeratin fragment modification by intracellular activated protease (14). Cytokeratin is one of the intermediate filament proteins from the cytoskeleton of epithelial cells (15) and the results of cytokeratin staining in this case also suggests that elevation of CYFRA is caused by the thymoma. Originally, CYFRA was used in the diagnosis, assessment of therapeutic effectiveness and evaluation of prognosis in cancers such as squamous cell carcinoma (16). Additionally, the present case demonstrated that CYFRA may be useful for the evaluation of thymoma with extensive necrosis. The serum CYFRA levels decreased without treatment in our patient, possibly reflecting the decreased tumor volume or massive necrotic reaction. We herein report a case of SR of thymoma. Although the frequency of this event is low, SR does not exclude malignancy and surgical intervention should be considered for the residual lesion. References 1 Moran MD and Suster S: Thymoma with prominent cystic and hemorrhagic changes and areas of necrosis and infarction: A clinicopathologic study of 25 cases. Am J Surg Pathol. 25:1086–1090. 2001. View Article : Google Scholar : PubMed/NCBI 2 Engels EA and Pfeiffer RM: Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 105:546–551. 2003. View Article : Google Scholar : PubMed/NCBI 3 Schmidt-Wolf IG, Rockstroh JK, Schüller H, et al: Malignant thymoma: Current status of classification and multimodality treatment. Ann Hematol. 82:69–76. 2003.PubMed/NCBI 4 Barratt S, Puthucheary ZA and Plummeridge M: Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms. Eur J Cardiothorac Surg. 31:1142–1143. 2007. View Article : Google Scholar : PubMed/NCBI 5 Moran CA and Suster S: ‘Ancient’ (sclerosing) thymomas: A clinicopathologic study of 10 cases. Am J Clin Pathol. 121:867–871. 2004. View Article : Google Scholar : PubMed/NCBI 6 Yutaka Y, Omasa M, Shikuma K, Okuda M and Taki T: Spontaneous regression of an invasive thymoma. Gen Thorac Cardiovasc Surg. 57:272–274. 2009. View Article : Google Scholar : PubMed/NCBI 7 Okagawa T, Uchida T and Suyama M: Thymoma with spontaneous regression and disappearance of pleural effusion. Gen Thorac Cardiovasc Surg. 55:515–517. 2007. View Article : Google Scholar : PubMed/NCBI 8 Fukui T, Taniguchi T, Kawaguchi K and Yokoi K: Spontaneous regression of thymic epithelial tumours. Interact Cardiovasc Thorac Surg. 18:399–401. 2014. View Article : Google Scholar : PubMed/NCBI 9 Cole WH: Spontaneous regression of cancer: The metabolic triumph of the host? Ann NY Acad Sci. 230:111–141. 1974. View Article : Google Scholar : PubMed/NCBI 10 Cole WH: Efforts to explain spontaneous regression of cancer. J Surg Oncol. 17:201–209. 1981. View Article : Google Scholar : PubMed/NCBI 11 Romi F: Thymoma in myasthenia gravis: From diagnosis to treatment. Autoimmune Dis. 2011:4745122011.PubMed/NCBI 12 Kuo T: Sclerosing thymoma - a possible phenomenon of regression. Histopathology. 25:289–291. 1994. View Article : Google Scholar : PubMed/NCBI 13 Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:61–66. 1993.PubMed/NCBI 14 Morita T, Kikuchi T, Hashimoto S, Kobayashi Y and Tokue A: Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Eur Urol. 32:237–244. 1997.PubMed/NCBI 15 Hsu JD, Yao CC, Lee MY, et al: True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol. 29:282–289. 2010. View Article : Google Scholar : PubMed/NCBI 16 Rastel D, Ramaioli A, Cornillie F and Thirion B: CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 30A:601–606. 1994. View Article : Google Scholar : PubMed/NCBI Related Articles
- 22 June 2015
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 3 (5) , 1058-1062
Thymoma exhibiting spontaneous regression in size, pleural effusion and serum cytokeratin fragment level: A case report
A 30-year-old man was admitted to Toho University Omori Medical Center for assessment of right chest pain and fever. Chest computed tomography (CT) revealed an anterior mediastinal tumor sized 11.0x6.0x5.0 cm, with right pleural effusion. The laboratory analysis revealed elevated white blood cell count (11,000/µl), C‑reactive protein (4.1 mg/dl) and cytokeratin fragment (CYFRA; 12.7 ng/ml; normal, Introduction Thymoma is derived from thymic epithelial cells and is one of the most common neoplasms in the anterior mediastinum (1). The overall incidence of thymoma is 0.15 cases per 100,000 individuals and the majority of the patients with thymoma or thymic carcinoma are aged 40–60 years (2,3). The World Health Organisation (WHO) classification is based on histological analysis of epithelial cell atypia and the degree of infiltration of non-neoplastic lymphocytes (4). Although the great majority of these tumors exhibit more conventional histological characteristics, unusual types have also been described, such as sclerosing thymoma (5). Spontaneous regression (SR) of thymoma without therapy has been reported, although its incidence is rare (6–8). This is the case report of a patient with thymoma exhibiting SR and disappearance of the pleural effusion. Case report A 30-year-old man was admitted to Toho University Omori Medical Center with right chest pain and low-grade fever. The patient was a never-smoker and had no medical history. On physical examination, the temperature was 37.8°C and the respiratory sounds were clear. A chest X-ray revealed a mass shadow in the right hilum and a blunted right costophrenic angle. A chest X-ray obtained 3 months prior had shown minor expansion of the right mediastinum, without any findings of right pleural effusion, but no additional examinations were performed. A chest computed tomography (CT) scan revealed an anterior mediastinal tumor sized 11.0×6.0×5.0 cm, with a right pleural effusion (Fig. 1). The laboratory analysis findings were normal, except for elevations of the white blood cell count (11,000/µl), C-reactive protein (4.1 mg/dl) and serum cytokeratin fragment (CYFRA; 12.7 ng/ml, normal, Time points Day Size, mm Reduction rate, % Pleural effusion CYFRA, ng/ml At first visit 0 110×60×50 – + 12.7 At CTNB 6 100×55×44 26.7 + – After CTNB (7 days) 13 95×54×42 34.7 – – After CTNB (1 month) 35 80×36×30 73.8 – 0.8 [i] CT, computed tomography; CYFRA, cytokeratin fragment; CTNB, CT-guided needle biopsy. The mediastinal mass adhered densely to the upper lobe of the right lung and thymectomy and partial resection of the right upper lobe were performed. The mediastinal mass was composed of a solid part and cystic space (Fig. 5A). In the solid part, there was epithelial cell proliferation admixed with a large number of lymphocytes, which was compatible with who type B2 thymoma (Fig. 5B). The tumor displayed coagulation necrosis and fibrosis, with foamy cell aggregations and cholesterol crystals (Fig. 5C). Microscopic transcapsular invasion was present (Masaoka classification, stage II). By contrast, the cystic wall was lined by a flattened epithelium including a small number of goblet cells. Thymic tissue with Hassall's corpuscles was attached to the thin-walled cyst, which was consistent with a thymic cyst. On immunohistochemical staining (Fig. 5D and E), the tumor was strongly positive for cytokeratin. The postoperative course was uneventful and the patient remains recurrence-free at 1 year after surgery. Figure 5. (A) Macroscopically, the resected specimen was composed of a solid mass with massive necrosis and a cystic space; (B) the mass in the right lobe is composed of epithelial cells admixed with lymphocytes; (C) the tumor included prominent degenerative and necrotic areas; (D) on CD5 immunohistochemical staining, the presence of T lymphocytes was demonstrated; (E) immunohistochemical staining was strongly positive for cytokeratin (AE1/AE3). Discussion SR has been reported in various types of cancer, although it is considered unusual (9). Cole (9,10) reported that immunological reactions play an important role in this rare event (10) and SR of tumors may be caused by necrosis and rupture (9). SR in mediastinal tumors has been reported in renal cell carcinoma, malignant melanoma and neuroblastoma (9). However, SR of thymoma is rare (6–8). Moran and suster (1) reported 25 cases of thymoma with prominent hemorrhagic and necrotic changes, without a detailed description of tumor regression. Thymoma is generally asymptomatic (1) and the majority of the patients with thymoma commonly present with an abnormal chest shadow, while 15% of the cases with thymoma are associated with myasthenia gravis (11). By contrast, all the reported patients with SR of thymoma have presented with symptoms, such as fever or chest pain (Table II). These symptoms may be associated with rapid tumor enlargement prior to regression, as was the case in our patient. One possible cause of the rapid enlargement of thymoma prior to regression has been reported to be disruption of the vascular supply and necrosis and an inflammatory reaction resulting in pleural effusion (6). All the patients with sr of thymoma presented with pleural effusion (Table II), supporting this hypothesis. In the present case, the tumor included prominent degenerative and necrotic areas, which was consistent with previous reports (Table II). Kuo (12) reported that a hemorrhagic and necrotic thymoma may develop into a sclerosing thymoma, due to the absorption of the hemorrhagic and necrotic components. Clinical findings such as fever, chest pain and elevation of serum levels of inflammatory markers are consistent with massive necrosis (12). The cause, mechanism and trigger of regression, as well as the cause of necrosis, have not been clearly determined and remain a hypothesis. Rapid tumor growth may lead to increased internal pressure, resulting in massive necrosis and subsequent tumor regression. In some patients, non-steroidal anti-inflammatory drugs were administered for subjective symptoms. Thymoma regression during corticosteroid treatment has been reported (4) and may be associated with stress and increased steroid levels. Some cases are believed to be caused by vascular insufficiency and thrombus formation (8), which was not observed in our patient. Table II. Reported cases of SR of thymoma. Table II. Reported cases of SR of thymoma. Symptoms Pathological findings No. Author Age, years Gender Chest pain Fever Masaoka stage Necrosis WHO type Size before SR, mm Pleural effusion CYFRA, ng/ml Size after SR, mm Reduction rate, % Duration of SR Refs. 1 Okagawa et al 31 F + + II + B2 60×55×50 + ND 45×40×30 67.3 3 weeks (7) 2 Yutaka et al 47 M + ND I + B3 80×70×60 + 40 60×30×20 89.3 1 month (6) 3 Fukui et al 43 F + ND II + B2 34×34×27 + ND 14×12×8 95.7 1.5 months (8) 4 Fukui et al 32 F + + IV + B2 100×95×79 + ND 73×69×49 63.1 1 week (8) 5 Present case 30 M + + II + B2 110×60×50 + 12.7 80×36×30 73.8 1 month – [i] WHO, World Health Organisation; M, male; F, female; ND, not described; SR, spontaneous regression; CYFRA, cytokeratin fragment. Elevation of CYFRA in the pleural effusion was prominent in the present case, suggesting that the origin of CYFRA may be the epithelial cells of the thymoma. CYFRA has been reported to be a sensitive and specific marker for squamous cell lung cancer, through detecting a fragment of the cytokeratin-19, which is a subunit of the cytokeratin intermediate filament expressed in simple epithelia and their malignant counterparts (13). In the present case, the level of CYFRA was increased in the serum and pleural effusion, which had not been previously reported (Table II). The increased CYFRA levels may be attributed by a collapse of tumor cells and increased cytokeratin fragment modification by intracellular activated protease (14). Cytokeratin is one of the intermediate filament proteins from the cytoskeleton of epithelial cells (15) and the results of cytokeratin staining in this case also suggests that elevation of CYFRA is caused by the thymoma. Originally, CYFRA was used in the diagnosis, assessment of therapeutic effectiveness and evaluation of prognosis in cancers such as squamous cell carcinoma (16). Additionally, the present case demonstrated that CYFRA may be useful for the evaluation of thymoma with extensive necrosis. The serum CYFRA levels decreased without treatment in our patient, possibly reflecting the decreased tumor volume or massive necrotic reaction. We herein report a case of SR of thymoma. Although the frequency of this event is low, SR does not exclude malignancy and surgical intervention should be considered for the residual lesion. References 1 Moran MD and Suster S: Thymoma with prominent cystic and hemorrhagic changes and areas of necrosis and infarction: A clinicopathologic study of 25 cases. Am J Surg Pathol. 25:1086–1090. 2001. View Article : Google Scholar : PubMed/NCBI 2 Engels EA and Pfeiffer RM: Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 105:546–551. 2003. View Article : Google Scholar : PubMed/NCBI 3 Schmidt-Wolf IG, Rockstroh JK, Schüller H, et al: Malignant thymoma: Current status of classification and multimodality treatment. Ann Hematol. 82:69–76. 2003.PubMed/NCBI 4 Barratt S, Puthucheary ZA and Plummeridge M: Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms. Eur J Cardiothorac Surg. 31:1142–1143. 2007. View Article : Google Scholar : PubMed/NCBI 5 Moran CA and Suster S: ‘Ancient’ (sclerosing) thymomas: A clinicopathologic study of 10 cases. Am J Clin Pathol. 121:867–871. 2004. View Article : Google Scholar : PubMed/NCBI 6 Yutaka Y, Omasa M, Shikuma K, Okuda M and Taki T: Spontaneous regression of an invasive thymoma. Gen Thorac Cardiovasc Surg. 57:272–274. 2009. View Article : Google Scholar : PubMed/NCBI 7 Okagawa T, Uchida T and Suyama M: Thymoma with spontaneous regression and disappearance of pleural effusion. Gen Thorac Cardiovasc Surg. 55:515–517. 2007. View Article : Google Scholar : PubMed/NCBI 8 Fukui T, Taniguchi T, Kawaguchi K and Yokoi K: Spontaneous regression of thymic epithelial tumours. Interact Cardiovasc Thorac Surg. 18:399–401. 2014. View Article : Google Scholar : PubMed/NCBI 9 Cole WH: Spontaneous regression of cancer: The metabolic triumph of the host? Ann NY Acad Sci. 230:111–141. 1974. View Article : Google Scholar : PubMed/NCBI 10 Cole WH: Efforts to explain spontaneous regression of cancer. J Surg Oncol. 17:201–209. 1981. View Article : Google Scholar : PubMed/NCBI 11 Romi F: Thymoma in myasthenia gravis: From diagnosis to treatment. Autoimmune Dis. 2011:4745122011.PubMed/NCBI 12 Kuo T: Sclerosing thymoma - a possible phenomenon of regression. Histopathology. 25:289–291. 1994. View Article : Google Scholar : PubMed/NCBI 13 Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:61–66. 1993.PubMed/NCBI 14 Morita T, Kikuchi T, Hashimoto S, Kobayashi Y and Tokue A: Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Eur Urol. 32:237–244. 1997.PubMed/NCBI 15 Hsu JD, Yao CC, Lee MY, et al: True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol. 29:282–289. 2010. View Article : Google Scholar : PubMed/NCBI 16 Rastel D, Ramaioli A, Cornillie F and Thirion B: CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 30A:601–606. 1994. View Article : Google Scholar : PubMed/NCBI Related Articles
- 1 April 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (4) , 483-487
Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
- 1 April 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (4) , 483-487
Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
- 1 August 2012
- Vol. 32 (8) , 3339-44
Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors. CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay. Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR mutation detection rates in cfDNA were significantly higher in patients with ≥ 2 CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001). The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.
- 1 August 2012
- Vol. 32 (8) , 3339-44
Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors. CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay. Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR mutation detection rates in cfDNA were significantly higher in patients with ≥ 2 CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001). The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.
- 2 May 2012
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 8 (3) , 260-266
Pathological response and prognosis of stage III non‐small cell lung cancer patients treated with induction chemoradiation
Aim: The aim of this study was to clarify the relationship between pathological effects and the prognosis of patients with stage III non‐small cell lung cancer (NSCLC) treated with induction chemoradiation.Methods: Patients who were untreated and potentially resectable with stage III NSCLC were enrolled. They received carboplatin and docetaxel with concurrent radiotherapy (5 × 2 Gy/week with a total dose of 40 Gy) followed by surgery. We assessed the relationship between the pathological effect (Ef) (Ef 1: slight pathological response, Ef 2: moderate pathological response, Ef 3: complete pathological response) and prognosis.Results: In all, 30 patients with stage III NSCLC (24 men and 6 women, mean age 60.7 years, 17 with adenocarcinomas and 13 with squamous cell carcinomas, 21 with clinical stage IIIA and nine with stage IIIB) participated in the trial and underwent induction chemoradiation. A total of 27 patients (90%) with complete response, partial response and stable disease had surgical resection. The pathological effect was Ef 1 and Ef 2 in 10 patients each, and Ef 3 in seven patients. Median survival was 10.9 months in patients with Ef 1 and 49.6 months in patients with Ef 2. Six out of seven Ef 3 patients are alive at the time of writing with a mean survival of 77.1 months (14–104 months). There was a significant difference in overall survival based on pathological effect rating (P = 0.0036).Conclusion: The Ef rating was well correlated with prognosis after induction chemoradiation.
- 2 May 2012
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 8 (3) , 260-266
Pathological response and prognosis of stage III non‐small cell lung cancer patients treated with induction chemoradiation
Aim: The aim of this study was to clarify the relationship between pathological effects and the prognosis of patients with stage III non‐small cell lung cancer (NSCLC) treated with induction chemoradiation.Methods: Patients who were untreated and potentially resectable with stage III NSCLC were enrolled. They received carboplatin and docetaxel with concurrent radiotherapy (5 × 2 Gy/week with a total dose of 40 Gy) followed by surgery. We assessed the relationship between the pathological effect (Ef) (Ef 1: slight pathological response, Ef 2: moderate pathological response, Ef 3: complete pathological response) and prognosis.Results: In all, 30 patients with stage III NSCLC (24 men and 6 women, mean age 60.7 years, 17 with adenocarcinomas and 13 with squamous cell carcinomas, 21 with clinical stage IIIA and nine with stage IIIB) participated in the trial and underwent induction chemoradiation. A total of 27 patients (90%) with complete response, partial response and stable disease had surgical resection. The pathological effect was Ef 1 and Ef 2 in 10 patients each, and Ef 3 in seven patients. Median survival was 10.9 months in patients with Ef 1 and 49.6 months in patients with Ef 2. Six out of seven Ef 3 patients are alive at the time of writing with a mean survival of 77.1 months (14–104 months). There was a significant difference in overall survival based on pathological effect rating (P = 0.0036).Conclusion: The Ef rating was well correlated with prognosis after induction chemoradiation.
- 27 December 2009
- Published by Wiley in Respirology
- Vol. 15 (1) , 88-92
Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti‐cancer therapy
Background and objective: To clarify the clinical characteristics and risk factors for acute respiratory deterioration following anti‐cancer therapy in patients with pulmonary fibrosis (PF) and lung cancer.Methods: Patients with primary lung cancer and PF were identified by review of medical records. Of the 865 consecutive patients with primary lung cancer who had been treated between June 1999 and September 2007, 53 were diagnosed as having PF. This retrospective study analysed the prevalence of and risk factors for acute respiratory deterioration after treatment of lung cancer in these patients.Results: Acute respiratory deterioration was found in 10 (24%) of the 41 patients who received anti‐cancer therapy, and six (60%) of these patients died of respiratory failure. The incidence of acute respiratory deterioration was 28% (8/29) after chemotherapy and 16% (2/12) after surgery. Mortality after acute respiratory deterioration was 50% (4/8) among patients with idiopathic PF and 100% (2/2) among the patients with PF associated with rheumatoid arthritis. Logistic regression analysis revealed that a higher smoking index (cigarettes smoked per day × years of smoking) was a significant risk factor for acute respiratory deterioration (odds ratio: 1.002, P = 0.025).Conclusions: Patients with lung cancer who have pre‐existing PF should be carefully managed because of their high risk for developing acute respiratory deterioration after anti‐cancer therapy.
- 27 December 2009
- Published by Wiley in Respirology
- Vol. 15 (1) , 88-92
Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti‐cancer therapy
Background and objective: To clarify the clinical characteristics and risk factors for acute respiratory deterioration following anti‐cancer therapy in patients with pulmonary fibrosis (PF) and lung cancer.Methods: Patients with primary lung cancer and PF were identified by review of medical records. Of the 865 consecutive patients with primary lung cancer who had been treated between June 1999 and September 2007, 53 were diagnosed as having PF. This retrospective study analysed the prevalence of and risk factors for acute respiratory deterioration after treatment of lung cancer in these patients.Results: Acute respiratory deterioration was found in 10 (24%) of the 41 patients who received anti‐cancer therapy, and six (60%) of these patients died of respiratory failure. The incidence of acute respiratory deterioration was 28% (8/29) after chemotherapy and 16% (2/12) after surgery. Mortality after acute respiratory deterioration was 50% (4/8) among patients with idiopathic PF and 100% (2/2) among the patients with PF associated with rheumatoid arthritis. Logistic regression analysis revealed that a higher smoking index (cigarettes smoked per day × years of smoking) was a significant risk factor for acute respiratory deterioration (odds ratio: 1.002, P = 0.025).Conclusions: Patients with lung cancer who have pre‐existing PF should be carefully managed because of their high risk for developing acute respiratory deterioration after anti‐cancer therapy.
- 5 December 2009
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 14 (6) , 497-501
Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients
Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) has been useful for the detection of recurrent lung cancer. However, such technology is expensive and is not always widely available. In this study, we evaluated the selected use of FDG-PET for lung cancer patients with re-elevated levels of serum carcinoembryonic antigen (CEA) after curative surgery. Among 327 patients who underwent curative resection for primary lung cancer from May 2002 through March 2007, 199 had adenocarcinoma, of whom 78 (39%) had elevated levels of serum CEA before treatment. After surgery, the level was monitored every 1 to 3 months. Re-elevation of CEA was recognized in 39 (50%) patients, 22 of whom underwent FDG-PET and were included in this study. FDG-PET images were visually inspected, and abnormally increased FDG uptake was interpreted as recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of PET in detecting recurrent lung cancer were determined. FDG-PET correctly identified 14 out of 15 relapses and gave true negative results in six out of seven remissions, i.e., one false-negative and one false-positive were observed. The sensitivity, specificity, positive predictive value, and negative predictive value were 93%, 86%, 93%, and 86%, respectively. In 64% of the patients with unexplained increased CEA levels, FDG-PET provided decisive diagnostic clues guiding further diagnostic and therapeutic interventions. The selected use of FDG-PET for patients with re-elevated serum CEA levels after surgery can be a practical and effective mode of surveillance for detecting recurrent lung cancer.
- 5 December 2009
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 14 (6) , 497-501
Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients
Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) has been useful for the detection of recurrent lung cancer. However, such technology is expensive and is not always widely available. In this study, we evaluated the selected use of FDG-PET for lung cancer patients with re-elevated levels of serum carcinoembryonic antigen (CEA) after curative surgery. Among 327 patients who underwent curative resection for primary lung cancer from May 2002 through March 2007, 199 had adenocarcinoma, of whom 78 (39%) had elevated levels of serum CEA before treatment. After surgery, the level was monitored every 1 to 3 months. Re-elevation of CEA was recognized in 39 (50%) patients, 22 of whom underwent FDG-PET and were included in this study. FDG-PET images were visually inspected, and abnormally increased FDG uptake was interpreted as recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of PET in detecting recurrent lung cancer were determined. FDG-PET correctly identified 14 out of 15 relapses and gave true negative results in six out of seven remissions, i.e., one false-negative and one false-positive were observed. The sensitivity, specificity, positive predictive value, and negative predictive value were 93%, 86%, 93%, and 86%, respectively. In 64% of the patients with unexplained increased CEA levels, FDG-PET provided decisive diagnostic clues guiding further diagnostic and therapeutic interventions. The selected use of FDG-PET for patients with re-elevated serum CEA levels after surgery can be a practical and effective mode of surveillance for detecting recurrent lung cancer.